HOSPICES CIVILS DE LYON
🇫🇷France
NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
Phase 4
Completed
- Conditions
- Neurofibromatosis Type 1
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 80
- Registration Number
- NCT00169611
- Locations
- 🇫🇷
Laurence LION-FRANCOIS, Lyon, France
Evaluation of the Efficacy and Safety of Recombinant Human Growth Hormone (rhGH) in the Treatment of Children With Short Bowel Syndrome
Phase 3
Completed
- Conditions
- Short Bowel Syndrome
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 14
- Registration Number
- NCT00169637
- Locations
- 🇫🇷
Alain LACHAUX, Lyon, France
Remission Evaluation Before Intensified Treatment in Lymphoma: Impact of Positron Emission Tomography (PET) Using Fluorine-18-Floro-Deoxyglucose (FDG) in the Therapeutic Prescription. Medico-Economic Randomised Study
Not Applicable
- Conditions
- Lymphoma
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 80
- Registration Number
- NCT00169598
- Locations
- 🇫🇷
Gilles Salles, Lyon, France
Peripheral and Coronary Endothelial Dysfunction In Type 2diabetic Patients- Role of Metformin
Phase 3
Terminated
- Conditions
- Coronary and Peripheral Endothelial Dysfunction
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2007-10-05
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 30
- Registration Number
- NCT00169624
- Locations
- 🇫🇷
Laurent SEBBAG, Lyon, France
LOW CYCLO: Study Evaluating the Benefit of Two Doses of Ciclosporine in de Novo Cardiac Transplant
Phase 4
- Conditions
- Cardiac Transplantion
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 106
- Registration Number
- NCT00159159
- Locations
- 🇫🇷
Pascale BOISSONNAT, Lyon, France
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.
Phase 2
- Conditions
- Acute Lymphocytic Leukemia
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 30
- Registration Number
- NCT00149136
- Locations
- 🇫🇷
Xavier THOMAS, Lyon, France
Low-dose Hydrocortisone in Acutely Burned Patients
Phase 4
Completed
- Conditions
- Burns
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 40
- Registration Number
- NCT00149123
- Locations
- 🇫🇷
Sylvie TISSOT, Lyon, France
Comparison of Three Different Strategies to Prevent Propofol Induced Pain During Infusion
Phase 3
- Conditions
- Induction of Total Intravenous General Anesthesia
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 200
- Registration Number
- NCT00146926
- Locations
- 🇫🇷
Grégoire CHATAIN, Lyon, France
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Phase 2
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 30
- Registration Number
- NCT00146913
- Locations
- 🇫🇷
Franck NICOLINI, Lyon, France
GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- Procedure: Sentinel Node ResectionProcedure: Conventional Axillary Dissection
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 1627
- Registration Number
- NCT00144898
- Locations
- 🇫🇷
Alain LEIZOROVICZ, Lyon, France
© Copyright 2025. All Rights Reserved by MedPath